Encision Stock

Encision EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Encision (ECIA) as of Aug 1, 2026 is -5.01. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -18.08 — a change of -72.30% (higher).

EV/EBIT

-5.01

YoY

-72.30%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Encision is 2026 -5.01 . EV/EBIT (Enterprise Value to EBIT) of Encision was 2025 -18.08 . It decreases by -72.30% higher compared to the previous year.

The Encision EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-3.38 base
Jan 1, 2020
-4.17 base
Jan 1, 2021
-36.64 base
Jan 1, 2022
-1.27 base
Jan 1, 2023
-2.11 base
Jan 1, 2024
-1.76 base
Jan 1, 2025
-11.25 base
Jan 1, 2026
-0.04 base
YEARPRICE-TO-EBIT
2026 -0.04
2025 -11.25
2024 -1.76
2023 -2.11
2022 -1.27
2021 -36.64
2020 -4.17
2019 -3.38
2018 1.23
2017 -0.99
2016 -0.68
2015 -0.22
2014 -0.42
2013 -0.95
2012 -1.52
2011 10.57
2010 2.18
2009 3.40
2008 -1.85
2007 -7.87
Access this data via the Eulerpool API

Encision Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Encision's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Encision's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Encision's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Encision grows earnings faster than its peers.

Encision Stock analysis

What does Encision do? Encision Inc is a leading provider of precision instruments for minimally invasive surgery, based in Boulder, Colorado. The company's history can be traced back to 1991 when it was founded by Kenneth Messier, an experienced surgeon. At that time, minimally invasive surgery was becoming increasingly popular as it offered patients smaller scars and less pain. However, the technology was not yet perfected and problems, particularly with the use of high-frequency electrocautery, kept arising. Messier recognized this problem and developed an innovative solution: AEM technology (Active Electrode Monitoring). Together with a colleague, Mark Weinstein, he founded Encision Inc to bring this technology to the market. Since then, the company has evolved into a leading provider of precision tools for minimally invasive surgery. Encision's business model is based on the production and distribution of medical devices and related consumables. Encision offers a wide range of surgical instruments, including AEM and non-AEM electrocautery devices, surgical monitors, fine cutting instruments, and trocars. These devices are used in various surgical disciplines such as gynecology, urology, and general medicine. One of Encision's main areas of focus is AEM technology, which reduces the risk of unintentional tissue burns during electrocautery. The AEM system continuously monitors the electrical impedance of the tissue and adjusts the high-frequency power as needed. Another important area for Encision is the development of disposable products such as electrodes, needles, and tubing sets. These products are intended for single-use and help minimize infection risks. Encision has also specialized in the development of instruments for laparoscopic surgery, a minimally invasive technique in which the operation is performed through small incisions in the body. Encision's laparoscopy instruments offer precise control and high performance to meet the demands of surgeons. Encision has sold over 2,500 devices to clinics and healthcare providers in North America and Europe. Most of the products are registered and certified in the USA. Encision places great emphasis on quality and innovation. The company has strict quality control measures to maintain the highest standards in production and the development of new products. Furthermore, it is committed to constantly developing new technologies and expanding its portfolio to meet customer needs. Overall, Encision Inc has experienced strong growth in recent years and has become a leading provider of surgical instruments in the minimally invasive surgery industry. With its focus on quality, innovation, and customer satisfaction, the company has built a solid reputation in the industry and is expected to continue being a key player in the future. The answer is "Encision Inc is a leading provider of precision instruments for minimally invasive surgery, based in Boulder, Colorado." Encision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Encision stock

EV/EBIT (Enterprise Value to EBIT) of Encision is -5.01 in 2026.

Access this data via the Eulerpool API

Valuation — Encision

All Key Metrics — Encision